DEFA14A: Dynavax Urges Stockholders to Vote for Director Nominees Amid Proxy Contest with Deep Track Capital

Dynavax is urging stockholders to vote for its director nominees at the upcoming Annual Meeting on June 11, 2025, highlighting the company's strong financial performance and strategic direction, while criticizing Deep Track Capital's proposed changes.

Summary

• Dynavax has filed definitive proxy materials and sent a letter to stockholders urging them to vote for its four director nominees.
• The company highlights its record financial and operational results, balanced capital allocation strategy, and meaningful board refreshment.
• Dynavax emphasizes its commercial success with HEPLISAV-B, achieving a 267% total stockholder return over the past five years.
• The company is executing a disciplined capital allocation framework, including a $200 million share repurchase program, with $128.8 million already executed as of the end of Q1 2025.
• Dynavax expects HEPLISAV-B net product revenue to be $305-$325 million in 2025.
• The company anticipates the U.S. hepatitis B adult vaccine market to reach over $900 million in annual sales by 2030, with HEPLISAV-B expected to achieve at least 60% market share.
• Dynavax is advancing its vaccine pipeline, including shingles and plague vaccine programs, leveraging its CpG 1018 adjuvant.
• The company has engaged with Deep Track Capital, a hedge fund, which is seeking to replace four of Dynavax's independent directors.
• Dynavax believes Deep Track's plan to increase the stock repurchase program, enter into royalty financing, and sell the company would destroy stockholder value.
• Dynavax has offered settlement proposals to Deep Track, including appointing up to two of Deep Track's independent candidates, but Deep Track has refused all offers.
• The company believes Deep Track's ultimate objective is to gain majority control of the Dynavax Board at the 2026 Annual Meeting to implement its value-destructive plan.

Sentiment

Score: 7

Explanation: The document conveys a generally positive sentiment regarding Dynavax's performance and future prospects, but the ongoing proxy contest introduces uncertainty and potential risks.

Positives

• Dynavax has achieved significant stockholder returns and market share growth.
• The company has a strong balance sheet and is returning capital to stockholders through a share repurchase program.
• Dynavax is advancing its vaccine pipeline and has a disciplined approach to corporate development.
• The company has a refreshed and highly qualified Board of Directors.
• Dynavax has made proactive corporate governance enhancements, including seeking stockholder approval to declassify the Board.
• Dynavax has a strong commercial execution, driving a significant increase in HEPLISAV-B net product revenue and U.S. market share.

Negatives

• Dynavax is facing a proxy contest with Deep Track Capital, which is seeking to replace four of its independent directors.
• Deep Track's proposed plan is considered value-destructive by Dynavax management.
• Deep Track's nominee, Mr. Erkman, was deemed unqualified to serve as a director by the Dynavax Board.
• The proxy contest is time-consuming and costly.

Risks

• The proxy contest with Deep Track Capital could disrupt Dynavax's strategy and operations.
• Deep Track's proposed plan could negatively impact stockholder value.
• Failure to achieve expected market share and revenue growth for HEPLISAV-B could impact financial performance.
• Risks related to commercializing and supplying HEPLISAV-B.
• Risks related to the implementation of long-term growth objectives.

Future Outlook

Dynavax expects 2025 to be a banner year for HEPLISAV-B with anticipated net product revenue of $305-$325 million and anticipates the U.S. hepatitis B adult vaccine market to reach over $900 million in annual sales by 2030, with HEPLISAV-B expected to achieve at least 60% total market share.

Management Comments

• Dynavax is executing a clear strategy that is generating record results and delivering strong returns for stockholders.
• Deep Track is seeking board seats to advance an agenda that would shortchange other stockholders.
• We remain unwavering in our commitment to act in the best interests of the Company and all stockholders.

Industry Context

The announcement highlights Dynavax's position in the competitive vaccine market, particularly in the hepatitis B segment, and its efforts to expand its pipeline and leverage its adjuvant technology. The proxy contest reflects increasing shareholder activism in the biotech industry, with hedge funds seeking to influence company strategy and board composition.

Comparison to Industry Standards

• Dynavax's 267% total stockholder return over the past five years significantly exceeds the performance of the NASDAQ Biotechnology Index and the S&P Biotechnology Select Industry Index.
• HEPLISAV-B's expected 60% market share in the U.S. hepatitis B adult vaccine market by 2030 would position it as a market leader, potentially surpassing competitors like GSK's Engerix-B and Merck's Recombivax HB.
• The $200 million share repurchase program demonstrates a commitment to returning capital to stockholders, a practice seen in other established biopharmaceutical companies like Amgen and Gilead Sciences.

Corporate Governance

Stakeholder Impact

• Shareholders: The outcome of the proxy contest will directly impact the company's strategy and potentially stockholder value.
• Employees: Uncertainty surrounding the company's future direction could affect employee morale and retention.
• Customers: Continued commercial success of HEPLISAV-B is crucial for maintaining market share and revenue growth.
• Suppliers: Stability of the company's operations is important for maintaining reliable supply chains.

Next Steps

• Stockholders to vote on director nominees at the Annual Meeting on June 11, 2025.
• Dynavax to continue executing its strategy and advancing its vaccine pipeline.
• Dynavax to continue engaging with Deep Track Capital in an attempt to reach a resolution.

Key Dates

Keywords

Dynavax, HEPLISAV-B, Deep Track Capital, Proxy Contest, Director Nominees, Stockholder Value, Vaccine, Board of Directors, Share Repurchase Program, Capital Allocation